Investigational immunotherapy MPDL3280A doubled the likelihood of survival compared with chemotherapy in people with NSCLC
14 May 2015 | By Victoria White
Roche has announced interim results from a global, randomised Phase II study (POPLAR) of MPDL3280A in people with previously treated NSCLC...